Skip to Content
Merck
All Photos(1)

Key Documents

MAB4100

Sigma-Aldrich

Anti-MRP1 Antibody, clone QCRL-1

clone QCRL-1, Chemicon®, from mouse

Synonym(s):

Multidrug Resistance Protein-1

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

QCRL-1, monoclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

flow cytometry: suitable
immunocytochemistry: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
western blot: suitable

isotype

IgG1

UniProt accession no.

shipped in

wet ice

Gene Information

human ... ABCC1(4363)

Related Categories

Specificity

Reacts with a defined linear epitope (aa 918-924) of MRP1, a 190 kDa transmembrane

phosphoglycoprotein overexpressed in various human multidrug resistant tumor cell lines

and tumors (Cole et al., 1992; Hipfner et al., 1994, 1996, 1999; Wright et al, 1998). Does not cross react with the mouse mrp1, or human MDR1, MDR3,

MRP2, MRP3, MRP4, MRP5 or MRP6 gene products.

Immunogen

Non-denatured membranes prepared from the human small cell lung cancer cell line, H69AR, which highly overexpresses MRP1 (Cole et al., 1992; Hipfner et al., 1994, 1999).

Application

Anti-MRP1 Antibody, clone QCRL-1 detects level of MRP1 & has been published & validated for use in FC, WB, IC, IH, IH(P).
Western Blot: 0.2 μg/mL, with HRP-conjugated anti mouse IgG (Hipfner et al., 1994, 1996).

Immunocytochemistry: 1:20 - 1:50 on paraformaldehyde-fixed (0.5% in PBS) or 70% methanol-fixed cytospin preparations (Hipfner et al., 1999).

Immunohistochemistry on formalin-fixed paraffini-embedded sections following antigen retrieval by microwave heating in citrate (Wright, et al., 1998).

Flow cytometry: 1:20 dilution on cells fixed in 0.5% paraformaldehyde in PBS for 30 minutes, followed by anti-mouse FITC (block and wash with solution containing 0.1% Tween) (Hipfner, et al., 1994).

Immunoprecipitation (Hipfner, et al., 1994; 1996).

Optimal working dilutions must be determined by the end user.

Physical form

Format: Purified
Purified immunoglobulin. Liquid in PBS with 0.1% sodium azide.

Storage and Stability

Store at 2-8ºC for up to 3 months. For longer term storage, aliquot and freeze at -20ºC.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

B B Weksler et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 19(13), 1872-1874 (2005-09-06)
Establishment of a human model of the blood-brain barrier has proven to be a difficult goal. To accomplish this, normal human brain endothelial cells were transduced by lentiviral vectors incorporating human telomerase or SV40 T antigen. Among the many stable
A rapid and quantitative coat protein complex II vesicle formation assay using luciferase reporters.
J Chris Fromme,Jinoh Kim
Analytical biochemistry null
Ligand-independent higher-order multimerization of CXCR4, a G-protein-coupled chemokine receptor involved in targeted metastasis.
Makiko Hamatake, Toru Aoki, Yuko Futahashi, Emiko Urano, Naoki Yamamoto, Jun Komano et al.
Cancer Science null
Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.
Frank Loganzo, Malathi Hari, Tami Annable, Xingzhi Tan, Daniel B Morilla, Sylvia Musto et al.
Molecular Cancer Therapeutics null
M J Kelner et al.
Anti-cancer drugs, 11(3), 217-224 (2000-06-01)
This study is part of an effort to evaluate efficacy of the novel agent MGI 114 (HMAF) against tumors resistant to conventional chemotherapeutic agents. MGI 114 is a novel semisynthetic anticancer agent currently in chemotherapeutic phase II trials to evaluate

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service